 CAMBRIDGE, Mass.--BUSINESS WIRE--Seres Therapeutics, Inc. Nasdaq: MCRB, a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection rCDI. SER-109 was associated with significantly greater reduction of antimicrobial resistance genes ARGs compared to placebo, with the reduction observed both rapidly by Week 1 and sustained through W 